#BEGIN_DRUGCARD DB01299

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
2447-57-6

# ChEBI_ID:
9329

# Chemical_Formula:
C12H14N4O4S

# Chemical_IUPAC_Name:
4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide

# Chemical_Structure:
Not Available

# Creation_Date:
2007-06-30 08:21:07 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents
Anti-Infective Agents, Urinary
Antimalarials

# Drug_Interactions:
Chlorpropamide	Sulfonamide/sulfonylurea: possible hypoglycemia
Methotrexate	The sulfamide increases the toxicity of methotrexate

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.70

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sulfadoxine

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)

# InChI_Key:
InChIKey=PJSFRIWCGOHTNF-UHFFFAOYSA-N

# Indication:
Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well.
Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected.

# KEGG_Compound_ID:
C07630

# KEGG_Drug_ID:
D00580

# LIMS_Drug_ID:
1299

# Mechanism_Of_Action:
Sulfadoxine is a sulfa drug, often used in combination with pyrimethamine  to treat malaria. This medicine may also be used to prevent malaria in people who are living in, or will be traveling to, an area where there is a chance of getting malaria. Sulfadoxine targets Plasmodium dihydropteroate synthase and dihydrofolate reductase.  Sulfa drugs or Sulfonamides are antimetabolites.  They compete with para-aminobenzoic acid (PABA) for incorporation into folic acid. The action of sulfonamides exploits the difference between mammal cells and other kinds of cells in their folic acid metabolism. All cells require folic acid for growth. Folic acid (as a vitamin) diffuses or is transported into human cells. However, folic acid cannot cross bacterial (and certain protozoan) cell walls by diffusion or active transport. For this reason bacteria must synthesize folic acid from p-aminobenzoic acid.

# Melting_Point:
190-194 Â°C

# Molecular_Weight_Avg:
310.329

# Molecular_Weight_Mono:
310.073575646

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451540

# Pharmacology:
Sulfadoxine helps inhibit the enzyme dihydropteroate synthetase which is an enzyme necessary in the conversion of PABA to folic acid. As folic acid is vital to the synthesis, repair, and methylation of DNA which is vital to cell growth in Plasmodium falciparum. With this vital nutrient lacking, the parasite has difficulty in reproducing.

# Predicted_LogP_Hydrophobicity:
0.72

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
2.96e-01 g/l

# Primary_Accession_No:
DB01299

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
17134

# PubChem_Substance_ID:
46507915

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:04 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
19220141	Lumb V, Das MK, Mittra P, Ahmed A, Kumar M, Kaur P, Dash AP, Singh SS, Sharma YD: Emergence of an unusual sulfadoxine-pyrimethamine resistance pattern and a novel K540N mutation in dihydropteroate synthetase in Plasmodium falciparum isolates obtained from Car Nicobar Island, India, after the 2004 Tsunami. J Infect Dis. 2009 Apr 1;199(7):1064-73.
19772548	Zhang GQ, Guan YY, Zheng B, Wu S, Tang LH: Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China. Trop Med Int Health. 2009 Oct;14(10):1266-71.
20439956	Raman J, Little F, Roper C, Kleinschmidt I, Cassam Y, Maharaj R, Barnes KI: Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg. 2010 May;82(5):788-94.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Z30658

# Drug_Target_1_GenBank_ID_Protein:
505177

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>1115 bp
TGATACCCGAATATAAGCATAATGTTTTAAATAATACCATCAGATGTTTATATAACAAAT
ATGTGAGTAGGATGAAAGAACAATATAATATAAATATTAAAGAAAATAATAAAAGGATAT
ATGTATTAAAAGATAGAATTTCTTATTTAAAAGAAAAAACAAATATTGTTGGAATATTAA
ATGTTAATTATGATTCTTTTTCAGATGGAGGTATTTTTGTTGAACCTAAACGTGCTGTTC
AAAGAATGTTTGAAATGATAAATGAAGGTGCTAGTGTTATAGATATAGGTGGAGAATCCG
CTGGTCCTTTTGTTATACCTAATCCAAAAATTAGTGAAAGAGATTTAGTAGTACCTGTAT
TACAATTATTTCAAAAAGAATGGAATGATATAAAAAATAAAATTGTTAAATGTGATGCGA
AACCAATTATAAGTATTGATACAATTAACTATAATGTTTTTAAAGAATGTGTTGATAATG
ATTTAGTTGATATATTAAATGATATTAGTGCTTGTACAAATAATCCAGAAATTATAAAAT
TATTAAAAAAAAAAAACAAATTCTATAGTGTAGTTCTAATGCATAAAAGAGGAAATCCAC
ATACAATGGATAAACTAACAAATTATGATAATCTAGTTTATGATATAAAAAATTATTTAG
AACAAAGATTAAATTTTCTTGTATTAAATGGAATACCTCGTTATAGGATACTATTTGATA
TTGGATTAGGATTTGCGAAGAAACATGATCAATCTATTAAACTCTTACAAAATATACATG
TATATGATGAGTATCCACTTTTTATTGGATATTCAAGAAAAAGATTTATTGCCCATTGCA
TGAATGATCAAAATGTTGTAATAAATACACAACAAAAATTACATGATGAACAACAAAATG
AAAATAAAAATATTGTGGACAAATCACACAATTGGATGTTTCAGATGAATTACATGAGGA
AAGACAAGGATCAACTTTTATATCAAAAAAATATATGTGGTGGATTAGCAATTGCTTCCT
ACAGCTATTATAAAAAGGTAGATCTAATAAGAGTTCATGACGTTTTAGAAACAAAATCGG
TTTTGGATGTTTTAACAAAAATAGACCAAGTGTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
7925353	Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE: Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994 Sep 1;224(2):397-405.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4116

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
43372

# Drug_Target_1_Name:
Dihydropteroate synthetase

# Drug_Target_1_Number_of_Residues:
370

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropteroate synthetase
IPEYKHNVLNNTIRCLYNKYVSRMKEQYNINIKENNKRIYVLKDRISYLKEKTNIVGILN
VNYDSFSDGGIFVEPKRAVQRMFEMINEGASVIDIGGESAGPFVIPNPKISERDLVVPVL
QLFQKEWNDIKNKIVKCDAKPIISIDTINYNVFKECVDNDLVDILNDISACTNNPEIIKL
LKKKNKFYSVVLMHKRGNPHTMDKLTNYDNLVYDIKNYLEQRLNFLVLNGIPRYRILFDI
GLGFAKKHDQSIKLLQNIHVYDEYPLFIGYSRKRFIAHCMNDQNVVINTQQKLHDEQQNE
NKNIVDKSHNWMFQMNYMRKDKDQLLYQKNICGGLAIASYSYYKKVDLIRVHDVLETKSV
LDVLTKIDQV

# Drug_Target_1_Reaction:
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate + 4-aminobenzoate = diphosphate + 7,8-dihydropteroate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q27738

# Drug_Target_1_SwissProt_Name:
Q27738_PLAFA

# Drug_Target_1_Synonyms:
EC 2.5.1.15

# Drug_Target_1_Theoretical_pI:
9.19

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15099990	Eriksen J, Mwankusye S, Mduma S, Kitua A, Swedberg G, Tomson G, Gustafsson LL, Warsame M: Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment. Trans R Soc Trop Med Hyg. 2004 Jun;98(6):347-53.
16023986	Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM: Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005 Sep;95(3):183-93.
17876469	Fernandes NE, Cravo P, do Rosario VE: [Sulfadoxine-pyrimethamine resistance in Maputo, Mozambique: presence of mutations in the dhfr and dhps genes of Plasmodium falciparum] Rev Soc Bras Med Trop. 2007 Jul-Aug;40(4):447-50.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M22159

# Drug_Target_2_GenBank_ID_Protein:
160260

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>1827 bp
ATGATGGAACAAGTCTGCGACGTTTTCGATATTTATGCCATATGTGCATGTTGTAAGGTT
GAAAGCAAAAATGAGGGGAAAAAAAATGAGGTTTTTAATAACTACACATTTAGAGGTCTA
GGAAATAAAGGAGTATTACCATGGAAATGTAATTCCCTAGATATGAAATATTTTCGTGCA
GTTACAACATATGTGAATGAATCAAAATATGAAAAATTGAAATATAAGAGATGTAAATAT
TTAAACAAAGAAACTGTGGATAATGTAAATGATATGCCTAATTCTAAAAAATTACAAAAT
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAATTTAAACCTTTAAGC
AATAGGATAAATGTTATATTGTCTAGAACCTTAAAAAAAGAAGATTTTGATGAAGATGTT
TATATCATTAACAAAGTTGAAGATCTAATAGTTTTACTTGGGAAATTAAATTACTATAAA
TGTTTTATTATAGGAGGTTCCGTTGTTTATCAAGAATTTTTAGAAAAGAAATTAATAAAA
AAAATATATTTTACTAGAATAAATAGTACATATGAATGTGATGTATTTTTTCCAGAAATA
AATGAAAATGAGTATCAAATTATTTCTGTTAGCGATGTATATACTAGTAACAATACAACA
TTGGATTTTATCATTTATAAGAAAACGAATAATAAAATGTTAAATGAACAAAATTGTATA
AAAGGAGAAGAAAAAAATAATGATATGCCTTTAAAGAATGATGACAAAGATACATGTCAT
ATGAAAAAATTAACAGAATTTTACAAAAATGTAGACAAATATAAAATTAATTATGAAAAT
GATGATGATGATGAAGAAGAAGATGATTTTGTTTATTTTAATTTTAATAAAGAAAAAGAA
GAGAAAAATAAAAATTCTATACATCCAAATGATTTTCAAATATATAATAGCTTGAAATAT
AAATATCATCCTGAATACCAATATTTAAATATTATTTATGATATTATGATGAATGGAAAT
AAACAAAGTGATCGAACGGGAGTAGGTGTTTTAAGTAAATTCGGATATATTATGAAATTT
GATTTAAGTCAATATTTCCCATTATTAACTACGAAGAAATTATTTTTAAGAGGAATTATT
GAAGAATTGCTTTGGTTTATTAGAGGAGAAACAAATGGTAATACGTTGTTAAATAAGAAT
GTAAGGATATGGGAAGCTAATGGTACTAGGGAATTTTTAGATAATAGAAAATTATTTCAT
AGAGAAGTTAACGATTTAGGACCTATTTATGGTTTTCAATGGAGACATTTCGGTGCTGAA
TATACAAATATGTATGATAATTATGAAAATAAAGGAGTGGATCAATTAAAAAATATAATA
AATTTAATTAAAAATGATCCTACAAGTAGAAGAATTCTTTTGTGTGCATGGAATGTAAAA
GATCTTGACCAAATGGCATTACCTCCTTGTCATATTTTATGTCAGTTTTATGTTTTCGAT
GGGAAATTATCATGTATTATGTATCAAAGATCATGTGATTTAGGGCTAGGAGTACCTTTT
AATATTGCTTCTTATTCTATTTTTACTCATATGATTGCACAAGTCTGTAATTTGCAACCT
GCGCAGTTCATACACGTTTTAGGAAATGCACATGTTTATAATAATCACATTGATAGTTTA
AAAATTCAACTTAACAGAATACCCTATCCATTCCCAACACTTAAATTAAATCCAGATATT
AAAAATATTGAAGATTTTACAATTTCGGATTTTACAATACAAAATTATGTTCATCATGAA
AAAATTTCAATGGATATGGCTGCTTAA

# Drug_Target_2_General_Function:
Nucleotide transport and metabolism

# Drug_Target_2_General_References:
2663650	Snewin VA, England SM, Sims PF, Hyde JE: Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene. 1989 Mar 15;76(1):41-52.
2677719	Zolg JW, Plitt JR, Chen GX, Palmer S: Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1989 Oct;36(3):253-62.
2825189	Bzik DJ, Li WB, Horii T, Inselburg J: Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8360-4.
3057499	Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ: Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9109-13.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
620

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
71818

# Drug_Target_2_Name:
Bifunctional dihydrofolate reductase-thymidylate synthase

# Drug_Target_2_Number_of_Residues:
608

# Drug_Target_2_PDB_ID:
1J3K

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00186	DHFR_1
PF00303	Thymidylat_synt

# Drug_Target_2_Protein_Sequence:
>Bifunctional dihydrofolate reductase-thymidylate synthase
MMEQVCDVFDIYAICACCKVESKNEGKKNEVFNNYTFRGLGNKGVLPWKCNSLDMKYFRA
VTTYVNESKYEKLKYKRCKYLNKETVDNVNDMPNSKKLQNVVVMGRTNWESIPKKFKPLS
NRINVILSRTLKKEDFDEDVYIINKVEDLIVLLGKLNYYKCFIIGGSVVYQEFLEKKLIK
KIYFTRINSTYECDVFFPEINENEYQIISVSDVYTSNNTTLDFIIYKKTNNKMLNEQNCI
KGEEKNNDMPLKNDDKDTCHMKKLTEFYKNVDKYKINYENDDDDEEEDDFVYFNFNKEKE
EKNKNSIHPNDFQIYNSLKYKYHPEYQYLNIIYDIMMNGNKQSDRTGVGVLSKFGYIMKF
DLSQYFPLLTTKKLFLRGIIEELLWFIRGETNGNTLLNKNVRIWEANGTREFLDNRKLFH
REVNDLGPIYGFQWRHFGAEYTNMYDNYENKGVDQLKNIINLIKNDPTSRRILLCAWNVK
DLDQMALPPCHILCQFYVFDGKLSCIMYQRSCDLGLGVPFNIASYSIFTHMIAQVCNLQP
AQFIHVLGNAHVYNNHIDSLKIQLNRIPYPFPTLKLNPDIKNIEDFTISDFTIQNYVHHE
KISMDMAA

# Drug_Target_2_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P13922

# Drug_Target_2_SwissProt_Name:
DRTS_PLAFK

# Drug_Target_2_Synonyms:
DHFR-TS

# Drug_Target_2_Theoretical_pI:
7.41

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01299
